Sequenom Using Obstetrix for Maternal Fetal Samples | GenomeWeb

NEW YORK (GenomeWeb News) — Maternal fetal medicine company Obstetrix Medical Group will provide Sequenom with samples that it will use to evaluate its prenatal screening test for Down syndrome, Sequenom said today.

The Sequenom Center for Molecular Medicine will evaluate up to 5,000 samples in a multi-center feasibility study for a non-invasive test using a maternal plasma marker. The test will assess Down syndrome using Sequenom's circulating cell-free fetal nucleic acid technology, the SEQureDx Trisomy 21 test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.